亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Tumor-homing CXCR4-expressing CTLs, Th1 and NK Cells, and Methods of Their Production and Use in Therapy of Cancer and Chronic Infections

详细技术说明
None
*Abstract
The Innovators discovered that hypoxia and small-molecule activators of hypoxia-inducible HIF-1-alpha (hypoxia mimetics) induce double-positive (CXCR4 /GZMB) CD 8 effector T cells. They in turn can migrate to tumor-produced CXCL12 and effectively kill cancer cells.BackgroundEffectiveness of immunity depends on proper homing of functionally-distinct subsets of T cells to different tissues. The ability of cytotoxic CD8 effector T cells (CTL/Teff), Th1- and NK cells to migrate to tumor- and chronically-inflamed tissues is critical for their ability eliminate cancer cells and intracellular infections. The induction of CXCR4 on killer cells could allow them to acquire a Trojan Horse status and exploit the pathway used by the tumors to attract suppressive cells, to enter tumors and kill cancer cells.Benefits1. The cells described by the innovators are simple to generate and require only low-cost procedures or reagents2. In case of hypoxia, no chemicals are used at all, facilitating incorporation of the innovators method into existing protocols 3. The possibility of generating ing cells with mixed phenotype for additional forms of treatment of cancer, infections, allergy, autoimmunity, and transplant rejectionApplicationUS Provisional Application FiledStage of DevelopmentIn Vitro Data
*Principal Investigation

Name: Pawel Kalinski, Assistant Professor of Surgery

Department: Med-Surgery


Name: Ravikumar Muthuswamy

Department: Med-Surgery

国家/地区
美国

欲了解更多信息,请点击 这里
移动设备